MapLight Therapeutics (MPLT) Corporate Presentation summary

Corporate overview and financial position

• Founded in 2018, employs over 100 people, and led by a team of experienced executives and scientists.

• Holds approximately $497M in pro forma cash as of September 30, 2025, providing a cash runway through 2027.

• Focuses on innovation with a broad and diversified product pipeline targeting neurological and psychiatric disorders.

Drug discovery and development approach

• Utilizes transcriptomics, optogenetics, and proprietary STARMAP platform to identify and validate neural circuit targets.

• Applies medicinal chemistry and pharmacokinetics to optimize drug candidates for brain-specific action.

Pipeline and lead programs

• Lead asset ML-007C-MA is a novel M₁/M4 muscarinic agonist in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis (ADP).

• Additional candidates include ML-004 (5-HT1B/1D agonist) for autism spectrum disorder (ASD) and ML-021/ML-009 for Parkinson's and hyperactivity/impulsivity.

• Pipeline leverages a circuit-based discovery platform for ongoing expansion into new indications.